Stockreport

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF Adding to existing ANKTIVA NMIBC approvals in the U.S. and U.K., and conditional approval in the European Union, the SFDA's action reflects ImmunityBio's mission to pro [Read more]